<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Causes of anemia in patients with cancer
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Causes of anemia in patients with cancer
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Causes of anemia in patients with cancer
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reed E Drews, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert T Means, Jr, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia frequently complicates the course of cancer. While anemia may be a presenting sign of malignancy, it may also be a consequence of a patient's antineoplastic therapy or progressive disease.
        </p>
        <p>
         Fatigue ranks as the most common symptom affecting cancer patients and limiting their daily activity. Since anemia is a frequent cause of fatigue, recognizing anemia and its causes is important for identifying appropriate interventions that may improve the cancer patient’s quality of life.
        </p>
        <p>
         This review will discuss those causes of anemia that are of specific relevance in patients with neoplastic disease.
        </p>
        <p>
         A general discussion of anemia and its treatment in patients with malignancy are presented separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia evaluation
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         <strong>
          of cancer-related anemia
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/2813.html" rel="external">
          "Cancer-related fatigue: Treatment", section on 'Anemic patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">
          "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perioperative optimization
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">
          "Perioperative blood management: Strategies to minimize transfusions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8168494">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H8168638">
         <span class="h2">
          Mechanisms
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with anemias in general, three broad categories should be considered when assessing causes of anemia in patients with malignancies. (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Red blood cell (RBC) losses from the body (blood loss anemia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased RBC destruction (hemolytic anemia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decreased RBC production (hypoproliferative anemia)
        </p>
        <p>
        </p>
        <p>
         Anemia may be "apparent" rather than real in patients with a normal RBC mass but an expanded plasma volume. This may be the result of fluid retention or volume expansion or the expanded plasma volume seen in patients with splenomegaly due to one of the myeloproliferative neoplasms. (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         .)
        </p>
        <p>
         Myelophthisis refers to displacement of hematopoietic cells by other cells or proteins not normally present in the bone marrow, such as tumor cells, fibrosis, or granulomas. It may be associated with leukoerythroblastic changes (teardrop cells and immature white blood cells) on the peripheral blood film. (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Leukoerythroblastic smear'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4001904513">
         <span class="h2">
          Causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia caused by one or more of these three mechanisms (see
         <a class="local">
          'Mechanisms'
         </a>
         above) can develop in the setting of cancer in three different ways:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A direct effect of the neoplasm (eg, bleeding from the tumor, bone marrow replacement).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An effect of a product of the neoplasm (eg, autoantibodies, microangiopathy, amyloid production, cytokine inhibition of erythropoiesis, paraneoplastic pure red cell aplasia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An effect of treatment directed against the neoplasm (eg, suppression of erythropoiesis by radiation therapy and/or systemic antineoplastic agents).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8168618">
         <span class="h2">
          Presence of multiple causes of anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple factors may contribute to the development of anemia in the cancer patient. In determining which factors may be contributory, it is important to correlate patients' clinical histories and physical exam findings with laboratory observations, realizing that more than one contributor may underlie the development of anemia. (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         .)
        </p>
        <p>
         As an example, a large prospective observational study evaluated multiple factors leading to the development of anemia in 888 patients with cancer,
         <strong>
          prior
         </strong>
         to the initiation of any cancer treatment. Observations included the following [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sixty-three percent of the patients in this study were anemic, with the incidence of anemia increasing with increasing cancer stage and decreasing Karnofsky performance status  (
         <a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemoglobin concentration was inversely correlated with the levels of inflammatory markers, hepcidin, ferritin, erythropoietin, reactive oxygen species, and the modified Glasgow Prognostic Score [
         <a href="#rid2">
          2
         </a>
         ], and positively correlated with leptin, albumin, cholesterol, and antioxidant enzymes.
        </p>
        <p>
        </p>
        <p>
         It was concluded that cancer-related anemia is a multifactorial problem, with immune, nutritional, and metabolic components affecting its severity.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          WHO and NCI CTCAE gradings of anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the World Health Organization (WHO) and National Cancer Institute (NCI), normal values for hemoglobin are 12 to 16 g/dL in adult females and 14 to 18 g/dL in adult males; the National Comprehensive Cancer Network (NCCN) suggests evaluation of anemia if the hemoglobin is ≤11 g/dL or if there is a decrease of ≥2 g/dL below the individual's baseline [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         For anemia that arises as a treatment-related toxicity, NCI common terminology criteria for adverse events (CTCAE) criteria for grading anemia are used  (
         <a class="graphic graphic_table graphicRef64984" href="/z/d/graphic/64984.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/90856.html" rel="external">
          "Common terminology criteria for adverse events", section on 'Hematologic'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ANEMIA FROM DIRECT EFFECTS OF NEOPLASMS
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Intraluminal bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intraluminal neoplasms arising from or metastatic to the gastrointestinal or genitourinary tract may bleed, producing blood loss anemia. Accordingly, when evaluating cancer patients who have anemia, stool and urine samples should be examined for the presence of blood, which may be occult. (See
         <a class="medical medical_review" href="/z/d/html/2544.html" rel="external">
          "Evaluation of occult gastrointestinal bleeding"
         </a>
         .)
        </p>
        <p>
         While the patient's hemoglobin, hematocrit, and red blood cell (RBC) indices may be normal in the early stages of blood loss, persistent bleeding will ultimately result in iron deficiency when the patient's iron stores become depleted. This usually occurs in males when total blood loss exceeds 1200 mL and in females at approximately 600 mL. (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Decreased concentrations of serum ferritin, reflecting deficient stores of iron, may be present. In addition, microcytic, hypochromic RBCs may be evident on review of peripheral blood smears  (
         <a class="graphic graphic_picture graphicRef64267" href="/z/d/graphic/64267.html" rel="external">
          picture 1
         </a>
         ). A progressive decrease over time in RBC mean corpuscular volume (MCV) and/or mean corpuscular hemoglobin (MCH) and/or mena corpuscular hemoglobin concentration (MCHC) is another clue that iron deficiency may be developing.
        </p>
        <p class="headingAnchor" id="H2290534782">
         <span class="h2">
          Intratumoral hemorrhage/rupture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Occasionally, acute anemia may occur due to spontaneous bleeding into the body of the tumor or rupture of the tumor into the peritoneum/retroperitoneum. Approximately 10 percent of hepatocellular cancers spontaneously rupture. The clinical picture is that of acute abdominal pain and distension, hypotension, and an acute drop in the hematocrit, and spontaneous liver rupture can occur with catastrophic consequences [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         Malignancies associated with hemorrhage into the tumor or rupture with risk of massive internal bleeding include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatocellular cancer [
         <a href="#rid4">
          4,5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">
          "Clinical features and diagnosis of hepatocellular carcinoma", section on 'Other clinical presentations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal stromal tumors, particularly those involving the stomach. (See
         <a class="medical medical_review" href="/z/d/html/7745.html" rel="external">
          "Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant hepatic epithelioid hemangioendothelioma [
         <a href="#rid4">
          4,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">
          "Pathology of malignant liver tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver metastases, especially from cutaneous or ocular melanomas [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Splenic hemangiosarcomas [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stromal ovarian tumors or cancers metastatic to the ovary [
         <a href="#rid9">
          9,10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">
          "Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retroperitoneal tumors with retroperitoneal hemorrhage [
         <a href="#rid11">
          11-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1082568870">
         <span class="h2">
          Generalized bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to bleeding from the tumor itself, effects of the malignancy on platelets and clotting factors can cause generalized bleeding. The following possible effects should be kept in mind [
         <a href="#rid15">
          15
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia-associated bleeding from treatment-associated bone marrow suppression. (See
         <a class="local">
          'Anemia from effects of cancer treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor-associated immune thrombocytopenia. (See
         <a class="medical medical_review" href="/z/d/html/4504.html" rel="external">
          "Overview of the complications of chronic lymphocytic leukemia", section on 'Thrombocytopenia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disseminated intravascular coagulation with coagulopathy-associated bleeding, which is especially common in pancreatic cancer and acute promyelocytic leukemia. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acquired autoantibodies inhibiting coagulation factors (eg, acquired von Willebrand disease, acquired factor VIII deficiency). Malignancy (in particular, lymphoproliferative disorders) is a risk factor for these acquired inhibitors [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/110531.html" rel="external">
          "Acquired von Willebrand syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1305.html" rel="external">
          "Acquired hemophilia A (and other acquired coagulation factor inhibitors)", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Not all bleeding episodes will be related to direct effects of the patient's malignancy. Preexisting bleeding disorders (eg, von Willebrand disease), bleeding lesions (eg, peptic ulcer disease), or use of anticoagulation may also contribute. Hemostatic testing (platelet count, coagulation studies, fibrinogen) may reveal these conditions. (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13284596">
         <span class="h2">
          Iron, vitamin B12, and folate deficiencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         While iron deficiency most commonly arises from bleeding, it may occasionally result from impaired iron absorption. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Intestinal iron absorption'
         </a>
         .)
        </p>
        <p>
         Iron malabsorption should be considered in patients with iron deficiency who do not respond to treatment with oral iron and/or whose malignancies involve the mucosa of the duodenum and/or upper jejunum, the sites of maximal iron absorption. This effect can be direct, as in gastrointestinal lymphoma [
         <a href="#rid18">
          18
         </a>
         ], or indirect, as in amyloidosis from multiple myeloma [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Folate deficiency is rare except in individuals with an extremely limited diet. (See
         <a class="medical medical_review" href="/z/d/html/7153.html" rel="external">
          "Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Inadequate dietary intake'
         </a>
         .)
        </p>
        <p>
         Intestinal involvement by neoplasms is unlikely to result in vitamin B12 deficiency, as body stores of vitamin B12 in the liver may be extensive, and vitamin B12 deficiency due to malabsorption generally takes years to develop. Vitamin B12 deficiency due to surgery for gastrointestinal tract cancer is discussed below. (See
         <a class="local">
          'Nutritional deficiencies after surgery for a GI tract malignancy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Hemophagocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemophagocytosis is characterized by ingestion of RBCs by macrophages or cancer cells. While the hemophagocytic syndrome (hemophagocytic lymphohistiocytosis [HLH]) is most commonly seen in association with infection, particularly Epstein-Barr virus (EBV) infection, this disorder can complicate certain malignancies, producing anemia in the absence of documented infection [
         <a href="#rid20">
          20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Malignancy'
         </a>
         .)
        </p>
        <p>
         Leukemias and lymphomas are the most common cancers associated with HLH. The latter are usually of T cell lineage, although NK cell, B cell, and myeloid proliferations causing hemophagocytosis have also been described [
         <a href="#rid21">
          21-24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4744.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma", section on 'Clinical presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4712.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         Interferon-gamma and monocyte-colony stimulating factor (M-CSF) levels may be elevated [
         <a href="#rid22">
          22
         </a>
         ]. Rarely, solid tumors demonstrate hemophagocytosis [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p>
         Detection of hemophagocytosis is generally made by bone marrow aspiration and biopsy, which reveals macrophages or cancer cells with ingested whole RBCs. (See
         <a class="medical medical_review" href="/z/d/html/4434.html" rel="external">
          "Evaluation of bone marrow aspirate smears", section on 'Macrophages (histiocytes) with ingested cells or debris'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Bone marrow infiltration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leukemias, lymphomas, and plasma cell dyscrasias commonly involve bone marrow, supplanting normal hematopoiesis and resulting in a process known as myelophthisis (see
         <a class="local">
          'Mechanisms'
         </a>
         above), causing anemia and other cytopenias. Solid tumors can also produce anemia by involvement of the bone marrow space with metastases.
        </p>
        <p>
         Disruption of the bone marrow microenvironment produces a leukoerythroblastic blood picture. This process is defined by the appearance of immature granulocytes, tear drop RBCs, and nucleated RBCs in peripheral blood  (
         <a class="graphic graphic_picture graphicRef55274 graphicRef68110" href="/z/d/graphic/55274.html" rel="external">
          picture 2A-B
         </a>
         ). Detection of this finding on review of a patient's peripheral blood smear should alert the clinician to the possibility of myelophthisic disease.
        </p>
        <p>
         While leukoerythroblastosis can arise from hematopoietic malignancies [
         <a href="#rid27">
          27
         </a>
         ], it is more commonly seen in patients with tumors metastatic to bone marrow  (
         <a class="graphic graphic_picture graphicRef70576" href="/z/d/graphic/70576.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid28">
          28
         </a>
         ]. In this instance, myelofibrosis and hepatosplenic extramedullary hematopoiesis appear to be important to the pathogenesis of the leukoerythroblastosis [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The myeloproliferative neoplasms are commonly associated with a leukoerythroblastic blood picture (eg, post-polycythemia myelofibrosis, post-essential thrombocythemia myelofibrosis, and primary myelofibrosis). (See
         <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">
          "Clinical manifestations and diagnosis of primary myelofibrosis", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Solid tumor types most commonly resulting in this disorder are prostatic, breast, and gastric carcinomas [
         <a href="#rid29">
          29,31-35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">
          "Clinical manifestations and diagnosis of primary myelofibrosis", section on 'Non-hematologic conditions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          ANEMIA FROM PRODUCTS OF THE NEOPLASM (INDIRECT EFFECTS)
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Amyloid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amyloid, either primary (AL) or secondary (AA), may deposit in a variety of organs including bone. While large bone deposits of amyloid (amyloidomas) may be seen, producing osteolytic lesions and pathologic fractures [
         <a href="#rid36">
          36
         </a>
         ], extensive replacement of bone marrow by amyloid is rare. Hence, anemia and other cytopenias are not a prominent feature of amyloidosis unless renal failure or coagulopathy is present. (See
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis", section on 'Systemic presentations'
         </a>
         .)
        </p>
        <p>
         While disorders causing secondary (AA) amyloid are chiefly chronic inflammatory and infectious diseases, malignant diseases giving rise to AA amyloid have been reported, including Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, renal cell carcinoma, and rarely, hepatocellular carcinoma [
         <a href="#rid37">
          37-44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Hematologic abnormalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemolysis, defined here as a shortening of RBC survival to less than 100 days, may occur in various malignancies. Two different mechanisms may be involved:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Production of autoantibodies that recognize red cell membrane antigens and cause an autoimmune hemolytic anemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Microangiopathic hemolysis
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Autoimmune hemolytic anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune hemolytic anemia (AIHA) is usually associated with the presence of immunoglobulin (IgG) or complement (C3d) on the surface of circulating RBCs, as detected by the direct antiglobulin (Coombs) test. (See
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Direct antiglobulin (Coombs) testing'
         </a>
         .)
        </p>
        <p>
         The presence of spherocytic RBCs on the peripheral smear, along with increased serum concentrations of indirect bilirubin and lactate dehydrogenase (LDH) and reduced concentrations of haptoglobin are the hallmark findings  (
         <a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">
          picture 4
         </a>
         ). While cancer-associated AIHA is most frequently noted in patients with chronic lymphocytic leukemia (CLL), other associated tumors include non-Hodgkin lymphoma, Hodgkin lymphoma, carcinomas, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, angioimmunoblastic T cell lymphoma (formerly termed angioimmunoblastic lymphadenopathy with dysproteinemia), acute lymphoblastic leukemia, and myelodysplasia. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         .)
        </p>
        <p>
         While the majority of AIHAs are due to warm-reacting antibodies, certain malignancies may be associated with cold-reacting antibodies. These include CLL, Waldenström macroglobulinemia, and the lymphomas. (See
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         .)
        </p>
        <p>
         AIHA may be exacerbated by
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         and other purine nucleoside analogs used in the treatment of certain indolent lymphoproliferative disorders such as CLL and follicular lymphoma [
         <a href="#rid45">
          45-47
         </a>
         ]. The mechanism is unclear, but may be related to altered T cell immunity and dysregulation of B cells, since fludarabine induces a decline in CD4 cells [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Direct antiglobulin (Coombs) testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Microangiopathic hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         In microangiopathic hemolytic anemia (MAHA), Coombs testing is negative, and schistocytes (RBC fragments) are the hallmark peripheral blood smear finding  (
         <a class="graphic graphic_picture graphicRef70851" href="/z/d/graphic/70851.html" rel="external">
          picture 5
         </a>
         ). MAHA with thrombocytopenia in malignancy may be a consequence of cancer-associated vascular endothelial injury (secondary thrombotic microangiopathy [TMA]) or disseminated intravascular coagulation (DIC).
        </p>
        <p>
         Most patients with cancer-related MAHA have already been diagnosed with cancer, although it can occasionally be a presenting sign of malignancy [
         <a href="#rid49">
          49
         </a>
         ]. However, many disorders other than cancer may trigger MAHA, particularly chemotherapy and other drugs, infection-associated sepsis, and DIC [
         <a href="#rid50">
          50
         </a>
         ]. Hence, implicating cancer as the cause of MAHA requires exclusion of these other causes. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         Both solid tumors and hematologic malignancies may give rise to MAHA [
         <a href="#rid51">
          51
         </a>
         ]. However, in contrast to leukemia-associated MAHA, which is generally due to DIC with risk of hemorrhage from consumptive coagulopathy (as in acute promyelocytic leukemia), solid tumor-associated MAHA is generally thrombotic, with an increased risk for thrombotic complications and renal failure. The solid tumors most commonly associated with MAHA are mucinous adenocarcinomas (eg, gastric, breast, pancreas, prostate, lung) [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3440162316">
         <span class="h4">
          DIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         In DIC, the primary findings are those of depletion of coagulation factors along with increases in fibrin degradation products and D-dimer  (
         <a class="graphic graphic_table graphicRef63831" href="/z/d/graphic/63831.html" rel="external">
          table 3
         </a>
         ). Peripheral blood schistocytes are generally few in number, whereas in TTP they are often plentiful and readily detectable on review of peripheral blood smears. Accordingly, serum LDH levels due to hemolysis and tissue ischemia are generally more strikingly elevated in TTP than in DIC, often reaching levels higher than 1000 international units/L [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Similarly, peripheral blood nucleated RBCs due to stress erythropoiesis are more common with TMA than with DIC. An exception might be DIC in association with leukoerythroblastosis from myelophthisis, which could cause nucleated RBCs on the blood smear. (See
         <a class="local">
          'Mechanisms'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         .)
        </p>
        <p>
         Mechanisms responsible for cancer-triggered DIC are uncertain. For example, tissue factor, the activator of factor VII, has been shown to be expressed on the surface of certain tumor cells [
         <a href="#rid56">
          56
         </a>
         ] as well as on circulating procoagulant microparticles in patients with malignancy [
         <a href="#rid57">
          57,58
         </a>
         ]. In addition, tumor necrosis factor and interleukin-6, proinflammatory cytokines associated with the malignant state, may dysregulate anticoagulant and antifibrinolytic mechanisms [
         <a href="#rid59">
          59,60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1353.html" rel="external">
          "Cancer-associated hypercoagulable state: Causes and mechanisms", section on 'Procoagulant proteins'
         </a>
         .)
        </p>
        <p>
         Cancer procoagulant (CP) is a calcium-dependent cysteine protease, which has been found in malignant and fetal tissue, but not normally differentiated tissue. It activates factor X directly, independent of the tissue factor/factor VIIa complex. CP is present in extracts of cells obtained from patients with acute promyelocytic leukemia (APL), malignant melanoma, and cancers of the colon, breast, lung, and kidney. (See
         <a class="medical medical_review" href="/z/d/html/1353.html" rel="external">
          "Cancer-associated hypercoagulable state: Causes and mechanisms", section on 'Procoagulant proteins'
         </a>
         .)
        </p>
        <p>
         APL is associated with a particularly high risk for DIC. The mechanism by which APL leads to DIC, which is often accompanied by secondary fibrinolysis, is incompletely understood. Three tumor cell procoagulants may be of primary importance (see
         <a class="medical medical_review" href="/z/d/html/1353.html" rel="external">
          "Cancer-associated hypercoagulable state: Causes and mechanisms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4527.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults", section on 'Coagulopathy and APL'
         </a>
         ). These are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tissue factor, which forms a complex with factor VII to activate factors X and IX.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cancer procoagulant, which activates factor X independent of factor VII.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased annexin II receptor expression on the surface of the leukemic promyelocytes [
         <a href="#rid61">
          61
         </a>
         ]. Annexin II receptor binds plasminogen and its activator, tissue plasminogen activator, increasing plasmin formation by a factor of 60.
        </p>
        <p>
        </p>
        <p>
         The induction of tumor cell differentiation with retinoic acid or
         <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">
          arsenic trioxide
         </a>
         can lead to rapid improvement in the coagulopathy and reduces the incidence of severe DIC in this disorder [
         <a href="#rid61">
          61,62
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">
          "Initial treatment of acute promyelocytic leukemia in adults", section on 'Control of coagulopathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3518864059">
         <span class="h4">
          Other TMAs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with TMAs other than DIC present with thrombocytopenia and a microangiopathic blood smear. Since primary TMAs primarily cause platelet consumption rather than clotting factor consumption (in particular, fibrinogen), levels of the coagulation components are usually normal, and there is little or no prolongation of the prothrombin time (PT) or activated partial thromboplastin time (aPTT). Measurement of fibrinogen and D-dimer also helps to clarify the situation, since these tests are generally normal in TMAs and abnormal in DIC. (See
         <a class="medical medical_review" href="/z/d/html/88648.html" rel="external">
          "Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'DIC versus other TMAs'
         </a>
         .)
        </p>
        <p>
         Secondary TMA in malignancy may be systemic, affecting numerous organs, or organ confined, as in hemolytic uremic syndrome (HUS), which primarily affects the kidney.
        </p>
        <p>
         Mechanisms of cancer-associated TMAs are less certain. It is presumed that direct endothelial injury is the initiating event in these settings [
         <a href="#rid63">
          63,64
         </a>
         ]. However, the onset of clinically evident disease may be delayed, frequently occurring months after chemotherapy has been discontinued or hematopoietic cell transplantation (HCT) has been performed [
         <a href="#rid65">
          65-67
         </a>
         ]. Affected patients typically present with slowly progressive renal failure, hypertension, and a relatively bland urine sediment, which may occur in the absence of clinically apparent tumor. (See
         <a class="medical medical_review" href="/z/d/html/1331.html" rel="external">
          "Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"
         </a>
         .)
        </p>
        <p>
         Alternatively, certain drugs used to treat the malignancy or HCT may incite TMA (referred to as drug-induced TMA [DITMA]) [
         <a href="#rid35">
          35,68
         </a>
         ]. DITMA may be due to an immune or a non-immune mechanism. The implicated drugs, mechanism, presentation, and management are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Anemia of chronic disease/anemia of inflammation (ACD/AI)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain cytokines (eg, interferon-alpha, interferon-beta, interferon-gamma, TNF-alpha, TGF-beta, IL-1, IL-6), produced in vivo in response to malignancy, may result in anemia by mediating a block in iron utilization, inhibiting erythropoietin mRNA synthesis, and exerting other ill-defined suppressive effects on erythropoiesis [
         <a href="#rid69">
          69-73
         </a>
         ]. IL-1, IL-6, and TNF-alpha induce increased levels of the iron-regulatory hormone hepcidin, which sequesters iron in macrophages, shunting iron away from erythropoiesis. In the case of Waldenström macroglobulinemia (WM), the lymphoplasmacytic cells of WM produce hepcidin [
         <a href="#rid74">
          74
         </a>
         ]. Variously known as the "anemia of chronic disease" (ACD) or "anemia of (chronic) inflammation," anemia due to inflammatory cytokines should be diagnosed after excluding other causes of anemia. (See
         <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">
          "Anemia of chronic disease/anemia of inflammation", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         While the anemia in ACD/AI is most often normocytic and normochromic, close review of peripheral blood smears will often reveal a small population of hypochromic, microcytic RBCs. Other findings include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abundant iron stores in bone marrow macrophages (unless concomitant blood loss has occurred) with decreased, if not absent, numbers of sideroblasts
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum erythropoietin (EPO) levels that are inappropriately low given the degree of anemia and intact renal function
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Low plasma concentrations of iron and transferrin (measured as total iron binding capacity [TIBC]) in the presence of normal or increased plasma ferritin concentrations. A low ratio of the soluble transferrin receptor (sTfR) to the serum ferritin may help to distinguish ACD from iron deficiency.
        </p>
        <p>
        </p>
        <p>
         These findings and the diagnostic evaluation are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">
          "Anemia of chronic disease/anemia of inflammation", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Pure red cell aplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Along with cancer, numerous drugs, chemicals, and non-malignant conditions may be responsible for the development of acquired pure red cell aplasia (PRCA). PRCA is a profound hypoproliferative anemia, characterized by markedly decreased or absent erythroid progenitors in the bone marrow, marked reticulocytopenia, and normal leukocyte and platelet counts. (See
         <a class="medical medical_review" href="/z/d/html/7120.html" rel="external">
          "Acquired pure red cell aplasia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1209222682">
         <span class="h3">
          Thymoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         In older series, thymomas accounted for as many as 50 percent of PRCA cases, with the incidence of PRCA in patients with thymomas ranging from 5 to 15 percent [
         <a href="#rid75">
          75-77
         </a>
         ]. Subsequent series, however, implicate thymomas less frequently [
         <a href="#rid78">
          78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4619.html" rel="external">
          "Clinical presentation and management of thymoma and thymic carcinoma", section on 'Paraneoplastic disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2810038497">
         <span class="h3">
          Hematologic malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Of the hematologic malignancies reported in association with PRCA, chronic lymphocytic leukemia (CLL) is one of the most frequently cited, with as many as 6 percent of CLL patients developing PRCA [
         <a href="#rid79">
          79
         </a>
         ]. Of these, two-thirds have B cell CLL and one-third have T cell CLL. However, in a Mayo Clinic series of 47 adults with acquired pure red blood cell aplasia, large granular lymphocyte (LGL) leukemia was the most common underlying cause [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16360.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia", section on 'Autoimmune disorders'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7120.html" rel="external">
          "Acquired pure red cell aplasia in adults", section on 'Secondary PRCA'
         </a>
         .)
        </p>
        <p>
         Other hematologic malignancies reported in association with PRCA include non-Hodgkin lymphomas, Hodgkin lymphoma, acute lymphoblastic leukemia, chronic myeloid leukemia, and multiple myeloma [
         <a href="#rid81">
          81,82
         </a>
         ]. While non-hematologic solid tumors have also been reported in association with PRCA, a cause-and-effect relationship between the patient's solid tumor and their PRCA has not been established in most cases [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         Mechanisms causing cancer-associated PRCA include [
         <a href="#rid77">
          77,83-87
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin inhibitors of erythropoietin responsive cells
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin-mediated cytotoxicity directed against erythroblasts
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T cell inhibition of erythropoietin-responsive cells
        </p>
        <p>
        </p>
        <p>
         Immunoglobulin inhibitors of erythropoietin have also been described; however, this mechanism as a cause of cancer-associated PRCA is much less common than mechanisms involving immunoglobulins directed against marrow erythroid cells [
         <a href="#rid88">
          88
         </a>
         ]. In PRCA associated with CLL, serum inhibitors of erythropoiesis have not been typically found. Rather, T lymphocytes appear to suppress erythroid growth in these patients, including those with B cell as well as T cell CLL [
         <a href="#rid89">
          89,90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1930.html" rel="external">
          "Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies", section on 'Etiology and pathogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Parvovirus B19 infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         While not an indirect effect of the neoplasm, it is important to keep in mind possible parvovirus B19 infection as a cause of PRCA, particularly in immunocompromised hosts. Parvovirus B19 selectively invades erythroid progenitors and can cause profound erythroid hypoplasia with erythroid maturation arrest, particularly with protracted infections arising in patients with altered immunity [
         <a href="#rid91">
          91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Chronic infection in immunosuppressed hosts'
         </a>
         .)
        </p>
        <p>
         Since patients with cancer are often immunosuppressed, either primarily by their malignancy or secondarily by therapy for their disease, parvovirus B19 infection must be considered as a possible cause of hypoproliferative anemia in such patients [
         <a href="#rid92">
          92
         </a>
         ]. In addition to profound erythroid hypoplasia with erythroid maturation arrest, a characteristic bone marrow finding in patients infected with parvovirus B19 is the presence of giant pronormoblasts with prominent eosinophilic intranuclear viral inclusions. Bone marrow biopsy can be highly informative in evaluating these patients  (
         <a class="graphic graphic_picture graphicRef51435" href="/z/d/graphic/51435.html" rel="external">
          picture 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7120.html" rel="external">
          "Acquired pure red cell aplasia in adults", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          ANEMIA FROM EFFECTS OF CANCER TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2456664458">
         <span class="h2">
          Bone marrow suppression from chemotherapy or radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most commonly, anemia in patients with cancer is the consequence of cancer therapy. Ionizing radiation encompassing sites of marrow hematopoiesis results in depletion of hematopoietic stem cells. However, systemic antineoplastic therapy is a more common cause of anemia than radiotherapy [
         <a href="#rid93">
          93,94
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stem cell death with long-term myelosuppression can occur following chemotherapy with non-cell-cycle-dependent drugs such as alkylators (
         <a class="drug drug_general" data-topicid="9658" href="/z/d/drug information/9658.html" rel="external">
          mitomycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         ), often in a dose-dependent fashion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Long-term myelodysplasia, often leading to acute myeloid leukemia, may be a consequence of the use of alkylating agents and inhibitors of topoisomerase II [
         <a href="#rid94">
          94-96
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4506.html" rel="external">
          "Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Non-myeloablative doses of chemotherapy agents (myelotoxic doses that do not require stem cell rescue) such as
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , anthracyclines,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , and
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         can cause actively proliferating committed progenitor cells to die, invariably yielding early short-term myelosuppression. Although usually short term, treatment-related myelosuppression may worsen in duration and severity as the number of treatment courses increases.
        </p>
        <p>
        </p>
        <p>
         Other mechanisms by which chemotherapy causes anemia include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suppression of hematopoietic growth factor synthesis, especially erythropoietin [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oxidant damage to mature hematopoietic cells [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Induction of immune-mediated hematopoietic cell destruction (eg,
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         )  (
         <a class="graphic graphic_table graphicRef109693" href="/z/d/graphic/109693.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid98">
          98-101
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia", section on 'Immune-mediated'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exacerbation of an underlying autoimmune hemolytic anemia associated with the patient's malignancy, as in
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         treatment of chronic lymphocytic leukemia [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="local">
          'Autoimmune hemolytic anemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Induction of microangiopathic hemolytic anemia, as in chemotherapy-induced thrombotic microangiopathy [
         <a href="#rid102">
          102
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute bone marrow stromal damage with intramedullary serofibrinous exudate and hemorrhage, particularly from high dose chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/4434.html" rel="external">
          "Evaluation of bone marrow aspirate smears", section on 'Bone marrow necrosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Management of symptomatic anemia from chemotherapy-induced myelosuppression may include transfusion of packed red blood cells (RBCs) and/or administration of an erythropoiesis-stimulating agent. (See
         <a class="medical medical_review" href="/z/d/html/2813.html" rel="external">
          "Cancer-related fatigue: Treatment", section on 'Transfusions versus ESAs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">
          "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H937485411">
         <span class="h2">
          Nutritional deficiencies after surgery for a GI tract malignancy
         </span>
        </p>
        <p class="headingAnchor" id="H1419748749">
         <span class="h3">
          Iron deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron malabsorption may also arise in patients who have had certain surgical operations involving the gastrointestinal (GI) tract, such as partial or total gastrectomy resulting in achlorhydria, gastric dumping, or afferent (blind) loop syndromes with or without bacterial overgrowth [
         <a href="#rid103">
          103-105
         </a>
         ]. If iron deficiency anemia is present and bleeding as a source of iron loss is not evident, disorders of impaired iron absorption should be considered. In such cases, an oral iron absorption test may be helpful [
         <a href="#rid18">
          18,106
         </a>
         ]. Intravenous iron may be required in such circumstances. (See
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults", section on 'Intravenous iron'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1865323975">
         <span class="h3">
          Vitamin B12 deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical removal of tumors involving the stomach (the source of intrinsic factor) or terminal ileum (the site of vitamin B12 absorption) may result in vitamin B12 deficiency. However, because body stores of vitamin B12 in the liver may be extensive, vitamin B12 deficiency may take years to develop following such surgery. (See
         <a class="medical medical_review" href="/z/d/html/7153.html" rel="external">
          "Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Causes of vitamin B12 deficiency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1699283728">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">
          "Society guideline links: Anemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H116045599">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics link (see
         <a class="medical medical_basics" href="/z/d/html/17028.html" rel="external">
          "Patient education: Anemia of inflammation (anemia of chronic disease) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes
         </strong>
         – Multiple factors may contribute to anemia in the cancer patient. It is important to correlate patients' clinical histories and physical examination findings with laboratory observations, since more than one contributing factor may be present. (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanisms
         </strong>
         – There are three general mechanisms for the development of anemia in any patient. One or more of these may be present in the anemic cancer patient:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blood loss, both local and generalized
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased red blood cell destruction (hemolysis)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased red blood cell production (bone marrow suppression)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mediators
         </strong>
         – Anemia caused by one of these mechanisms can develop in the setting of cancer in several ways:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A direct effect of the neoplasm (eg, bleeding from the tumor, bone marrow replacement). (See
         <a class="local">
          'Anemia from direct effects of neoplasms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A factor produced by the cancer cells (eg, autoantibodies, amyloid, cytokines that inhibit erythropoiesis, paraneoplastic phenomena that cause pure red cell aplasia [PRCA]). (See
         <a class="local">
          'Anemia from products of the neoplasm (indirect effects)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An effect of cancer treatment (eg, suppression of erythropoiesis by radiation therapy and/or chemotherapeutic agents). (See
         <a class="local">
          'Anemia from effects of cancer treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4004756806">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 2015; 100:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39:534.
          </a>
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf (Accessed on October 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewar GA, Griffin SM, Ku KW, et al. Management of bleeding liver tumours in Hong Kong. Br J Surg 1991; 78:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava DN, Gandhi D, Julka PK, Tandon RK. Gastrointestinal hemorrhage in hepatocellular carcinoma: management with transheptic arterioembolization. Abdom Imaging 2000; 25:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JW, Li Y, Xie K, et al. Spontaneous rupture of hepatic epithelioid hemangioendothelioma: A case report. World J Gastroenterol 2017; 23:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooperman AM, Weiland LH, Welch JS. Massive bleeding from a ruptured metastatic hepatic melanoma treated by hepatic lobectomy. Case report and review of the literature. Mayo Clin Proc 1976; 51:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Autry JR, Weitzner S. Hemangiosarcoma of spleen with spontaneous rupture. Cancer 1975; 35:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Margolin KA, Pak HY, Esensten ML, Doroshow JH. Hepatic metastasis in granulosa cell tumor of the ovary. Cancer 1985; 56:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LITTON MA, LITTON EW, FOX TC. HEMORRHAGE FROM A GRANULOSA-THECA CELL TUMOR OF THE OVARY; (AN UNUSUAL CAUSE OF ACUTE ABDOMINAL PAIN IN A CHILD). Wis Med J 1965; 64:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witz M, Bernheim J, Dinbar A, Griffel B. Kidney fibroxanthoma (malignant fibrous xanthoma): a rare tumor and an unusual cause of retroperitoneal hemorrhage. J Surg Oncol 1984; 26:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witz M, Shpitz B, Dinbar A. Massive intraabdominal bleeding due to a retroperitoneal leiomyosarcoma. J Surg Oncol 1983; 24:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen HT, Wolf JS Jr, Nash PA, et al. Acute retroperitoneal hemorrhage due to transitional cell carcinoma of the renal pelvis. J Urol 1995; 153:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swift DL, Lingeman JE, Baum WC. Spontaneous retroperitoneal hemorrhage: a diagnostic challenge. J Urol 1980; 123:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escobar MA. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor? Cancer 2012; 118:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicol C, Pan-Petesch B, Ianotto JC. Acquired von Willebrand syndrome and lymphoid neoplasms: A review of malignancy management, and propositions of practical recommendations. Haemophilia 2022; 28:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohri H. Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management. J Thromb Thrombolysis 2003; 15:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid TJ 3rd, Stamm CP, Dunning DM, Redmond J 3rd. Iron malabsorption in a patient with large cell lymphoma involving the duodenum. Am J Gastroenterol 1992; 87:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauth J, de Coning JP, Politzer WM, et al. Unusual presentation of multiple myeloma. A report of 2 cases. S Afr Med J 1984; 65:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaffey MJ, Frierson HF Jr, Medeiros LJ, Weiss LM. The relationship of Epstein-Barr virus to infection-related (sporadic) and familial hemophagocytic syndrome and secondary (lymphoma-related) hemophagocytosis: an in situ hybridization study. Hum Pathol 1993; 24:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aung W, Koslosky W, Chin NW, Pincus MR. Diffuse large cell lymphoma of B-cell type associated with reactive hemophagocytosis. Ann Clin Lab Sci 1996; 26:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi Y, Uehara S, Inamori K, et al. Hemophagocytosis as a para-neoplastic syndrome in NK cell leukemia. Int J Hematol 1996; 64:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imashuku S, Hibi S, Sako M, et al. Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22): common morphologic characteristics for this type of leukemia. Cancer 2000; 88:1970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet 2014; 383:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsoi WC, Feng CS. Hemophagocytosis by rhabdomyosarcoma cells in bone marrow. Am J Hematol 1997; 54:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Molad Y, Stark P, Prokocimer M, et al. Hemophagocytosis by small cell lung carcinoma. Am J Hematol 1991; 36:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis. Cancer 1991; 67:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubins JM. The role of myelofibrosis in malignant leukoerythroblastosis. Cancer 1983; 51:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delsol G, Guiu-Godfrin B, Guiu M, et al. Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance. Cancer 1979; 44:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Keane JC, Wolf BC, Neiman RS. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma. Cancer 1989; 63:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71:3594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013; 39:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park) 2011; 25:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott MA, Letendre L, Gastineau DA, et al. Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration. Eur J Haematol 2010; 85:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masias C, Vasu S, Cataland SR. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood 2017; 129:2857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kavanaugh JH. Multiple myeloma, amyloid arthropathy, and pathological fracture of the femur: a case report. J Bone Joint Surg Am 1978; 60:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanjewar DN, Raghuwanshi SR, Gupta D, et al. Systemic amyloidosis in Hodgkin's disease. Indian J Pathol Microbiol 1998; 41:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez Equiza E, Arguiñano JM, Gastearena J. Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin. Haematologica 1999; 84:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmonds PD, Cottrell BJ, Mead GM, et al. Lymphadenopathy due to amyloid deposition in non-Hodgkin's lymphoma. Ann Oncol 1997; 8:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia. J Clin Oncol 1993; 11:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coakley FV, Hricak H, Presti JC Jr, Small EJ. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. Br J Radiol 1999; 72:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgado MA, Liu JY, Meleg-Smith S. Systemic amyloidosis associated with hepatocellular carcinoma. Case report and literature review. J La State Med Soc 1999; 151:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terrier B, Jaccard A, Harousseau JL, et al. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) 2008; 87:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane T, Pinney JH, Gilbertson JA, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid 2017; 24:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez H, Leblond V, Azar N, et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 1998; 40:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998; 16:1885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 Suppl 1:S41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YC, Chang HK, Sun CF, Shih LY. Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin. South Med J 1995; 88:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 1996; 10:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laffay DL, Tubbs RR, Valenzuela R, et al. Chronic glomerular microangiopathy and metastatic carcinoma. Hum Pathol 1979; 10:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockhart AC. Microangiopathic haemolytic anaemia in metastatic malignancy. Hosp Med 2001; 62:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morton JM, George JN. Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. J Oncol Pract 2016; 12:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol 2007; 62:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27:4834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8:5588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu HH, Guo ZP, Jia JS, et al. The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Leuk Res 2018; 65:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groff JA, Kozak M, Boehmer JP, et al. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porta C, Danova M, Riccardi A, et al. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 1999; 74:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AM, Rose BD, Graff LG, et al. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Lelie H, Baars JW, Rodenhuis S, et al. Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. Cancer 1995; 76:2338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:1847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Means RT Jr. Advances in the anemia of chronic disease. Int J Hematol 1999; 70:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008; 14:3262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohaus S, Massini G, Giachelia M, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010; 28:2538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int 2011; 107:1893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciccarelli BT, Patterson CJ, Hunter ZR, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           JACOBS EM, HUTTER RV, POOL JL, LEY AB. Benign thymoma and selective erythroid aplasia of the bone marrow. Cancer 1959; 12:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirst E, Robertson TI. The syndrome of thymoma and erythroblastopenic anemia. A review of 56 cases including 3 case reports. Medicine (Baltimore) 1967; 46:225.
          </a>
         </li>
         <li class="breakAll">
          Dessypris EN. Pure Red Cell Aplasia, Johns Hopkins University Press, Baltimore 1988.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996; 87:4831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chikkappa G, Zarrabi MH, Tsan MF. Pure red-cell aplasia in patients with chronic lymphocytic leukemia. Medicine (Baltimore) 1986; 65:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carloss HW, Saab GA, Tavassoli M. Pure red cell aplasia and lymphoma. JAMA 1979; 242:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Means RT Jr. Pure red cell aplasia. Blood 2016; 128:2504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krantz SB. Pure red-cell aplasia. N Engl J Med 1974; 291:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abkowitz JL, Kadin ME, Powell JS, Adamson JW. Pure red cell aplasia: lymphocyte inhibition of erythropoiesis. Br J Haematol 1986; 63:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi S, Shibuya T, Morioka E, et al. Demonstration of three distinct immunological disorders on erythropoiesis in a patient with pure red cell aplasia and autoimmune haemolytic anaemia associated with thymoma. Br J Haematol 1988; 68:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masuda M, Arai Y, Okamura T, Mizoguchi H. Pure red cell aplasia with thymona: evidence of T-cell clonal disorder. Am J Hematol 1997; 54:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada O, Yun-Hua W, Motoji T, Mizoguchi H. Clonal T-cell proliferation causing pure red cell aplasia in chronic B-cell lymphocytic leukaemia: successful treatment with cyclosporine following in vitro abrogation of erythroid colony-suppressing activity. Br J Haematol 1998; 101:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peschle C, Marmont AM, Marone G, et al. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975; 30:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangan KF, Chikkappa G, Scharfman WB, Desforges JF. Evidence for reduced erythroid burst (BFUE) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia. Exp Hematol 1981; 9:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujisao S, Tsuda H. Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma. Br J Haematol 1998; 103:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frickhofen N, Chen ZJ, Young NS, et al. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asbell SO, Leon SA, Tester WJ, et al. Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy. Prostate 1996; 29:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedersen-Bjergaard J. Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leuk Res 1992; 16:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremin P, Flattery M, McCann SR, Daly PA. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Ann Oncol 1996; 7:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23:1161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995; 95:1650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doll DC, Weiss RB. Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 1985; 69:777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marani TM, Trich MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996; 36:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habibi B. Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 1985; 61:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clin Colorectal Cancer 2005; 5:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruntsch U, Groos G, Tigges FJ, Gallmeier WM. Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients. Eur J Cancer Clin Oncol 1984; 20:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutton DR, Baird IM, Stewart JS, et al. Gastrointestinal iron losses in atrophic gastritis, postgastrectomy states and adult coeliac disease. Gut 1971; 12:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimber C, Patterson JF, Weintraub LR. The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance. JAMA 1967; 202:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schade SG, Cohen RJ, Conrad ME. Effect of hydrochloric acid on iron absorption. N Engl J Med 1968; 279:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekenved G. Iron absorption studies. Studies on oral iron preparations using serum iron and different radioiron isotope techniques. Scand J Haematol Suppl 1976; 28:1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7140 Version 39.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239265" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22995477" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22995477" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1851653" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Management of bleeding liver tumours in Hong Kong.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10926190" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Gastrointestinal hemorrhage in hepatocellular carcinoma: management with transheptic arterioembolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28104995" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Spontaneous rupture of hepatic epithelioid hemangioendothelioma: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/943677" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Massive bleeding from a ruptured metastatic hepatic melanoma treated by hepatic lobectomy. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1167482" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hemangiosarcoma of spleen with spontaneous rupture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3891073" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hepatic metastasis in granulosa cell tumor of the ovary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14344331" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : HEMORRHAGE FROM A GRANULOSA-THECA CELL TUMOR OF THE OVARY; (AN UNUSUAL CAUSE OF ACUTE ABDOMINAL PAIN IN A CHILD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6738061" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Kidney fibroxanthoma (malignant fibrous xanthoma): a rare tumor and an unusual cause of retroperitoneal hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6632894" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Massive intraabdominal bleeding due to a retroperitoneal leiomyosarcoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7966750" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute retroperitoneal hemorrhage due to transitional cell carcinoma of the renal pelvis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7365905" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Spontaneous retroperitoneal hemorrhage: a diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21720995" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36006003" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acquired von Willebrand syndrome and lymphoid neoplasms: A review of malignancy management, and propositions of practical recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14739623" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1415109" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Iron malabsorption in a patient with large cell lymphoma involving the duodenum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6729646" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Unusual presentation of multiple myeloma. A report of 2 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8389318" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The relationship of Epstein-Barr virus to infection-related (sporadic) and familial hemophagocytic syndrome and secondary (lymphoma-related) hemophagocytosis: an in situ hybridization study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8879361" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Diffuse large cell lymphoma of B-cell type associated with reactive hemophagocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8854571" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hemophagocytosis as a para-neoplastic syndrome in NK cell leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10760776" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Hemophagocytosis by leukemic blasts in 7 acute myeloid leukemia cases with t(16;21)(p11;q22): common morphologic characteristics for this type of leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24290661" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Adult haemophagocytic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9092697" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hemophagocytosis by rhabdomyosarcoma cells in bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1849348" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hemophagocytosis by small cell lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1991302" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical significance of hematologic parameters in non-Hodgkin's lymphoma at diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6821819" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The role of myelofibrosis in malignant leukoerythroblastosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/476585" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2924261" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8490908" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23390027" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22010388" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20331741" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28416509" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : None of the above: thrombotic microangiopathy beyond TTP and HUS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/415063" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Multiple myeloma, amyloid arthropathy, and pathological fracture of the femur: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9670629" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Systemic amyloidosis in Hodgkin's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10091401" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9137796" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Lymphadenopathy due to amyloid deposition in non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8487054" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10474508" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Diffuse retroperitoneal amyloidosis due to renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11284149" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Systemic amyloidosis associated with hepatocellular carcinoma. Case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344807" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28686088" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547072" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9698219" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9586905" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9471060" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Complications in the treatment of CLL with purine analogues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7777893" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10451465" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8707760" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Hemolytic disorders associated with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/468225" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Chronic glomerular microangiopathy and metastatic carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11338960" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Microangiopathic haemolytic anaemia in metastatic malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27288467" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9590492" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8574967" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17293122" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Cancer-associated thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19738116" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Role of tissue factor in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2854203" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2188129" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Activation of coagulation after administration of tumor necrosis factor to normal subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10099141" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Annexin II and bleeding in acute promyelocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29232592" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9016902" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10377931" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6203452" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11328282" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8635040" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25372103" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Syndromes of thrombotic microangiopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1391934" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Progress in understanding the pathogenesis of the anemia of chronic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10446488" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Advances in the anemia of chronic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519751" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Involvement of hepcidin in the anemia of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20406921" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21070572" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21454222" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13618856" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Benign thymoma and selective erythroid aplasia of the bone marrow.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5338297" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The syndrome of thymoma and erythroblastopenic anemia. A review of 56 cases including 3 case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5338297" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : The syndrome of thymoma and erythroblastopenic anemia. A review of 56 cases including 3 case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639856" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The pathophysiology of pure red cell aplasia: implications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3091991" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pure red-cell aplasia in patients with chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639922" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/582187" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Pure red cell aplasia and lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27881371" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4604991" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Pure red-cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3085703" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pure red cell aplasia: lymphocyte inhibition of erythropoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3132200" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Demonstration of three distinct immunological disorders on erythropoiesis in a patient with pure red cell aplasia and autoimmune haemolytic anaemia associated with thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9092690" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Pure red cell aplasia with thymona: evidence of T-cell clonal disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9609530" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Clonal T-cell proliferation causing pure red cell aplasia in chronic B-cell lymphocytic leukaemia: successful treatment with cyclosporine following in vitro abrogation of erythroid colony-suppressing activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1201224" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6972322" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Evidence for reduced erythroid burst (BFUE) promoting function of T lymphocytes in the pure red cell aplasia of chronic lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827897" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Th1/Th2 balance alteration in the clinical course of a patient with pure red cell aplasia and thymoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7986722" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Parvovirus B19 as a cause of acquired chronic pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10910942" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8876707" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1732675" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8905034" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10382956" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7706473" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Cisplatin-associated anemia: an erythropoietin deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3160460" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Hemolytic anemia associated with antineoplastic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8937414" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Carboplatin-induced immune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2864949" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16356307" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6540191" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5123303" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Gastrointestinal iron losses in atrophic gastritis, postgastrectomy states and adult coeliac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5300146" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5670905" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Effect of hydrochloric acid on iron absorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1064900" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Iron absorption studies. Studies on oral iron preparations using serum iron and different radioiron isotope techniques.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
